APGE
Apogee Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$135.07
+0.00%0
Insider buys (3m)
11
Insider sells (3m)
-$19.9M
Net value (3m)
+60.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 11, 2026 | Fairmount Funds Management LLC · director | M-Exempt | 10,370 | $44 |
| Aug 11, 2026 | Fairmount Funds Management LLC · director | M-Exempt | 31,838 | $17 |
| Aug 7, 2026 | Dambkowski Carl · officer: Chief Medical Officer | M-Exempt | 4,125 | $23 |
| Aug 7, 2026 | Dambkowski Carl · officer: Chief Medical Officer | Sale | 5,500 | $134 |
| Jul 10, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 20,000 | $134 |
| Jul 2, 2026 | Dambkowski Carl · officer: Chief Medical Officer | Sale | 5,500 | $133 |
| Jul 2, 2026 | Dambkowski Carl · officer: Chief Medical Officer | M-Exempt | 4,125 | $23 |
| Jun 24, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 80,000 | $133 |
| Jun 24, 2026 | Dambkowski Carl · officer: Chief Medical Officer | Sale | 26,400 | $133 |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 1,080 | $84 |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 6,770 | $82 |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 7,654 | $83 |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 614 | $87 |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 2,305 | $86 |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 1,577 | $85 |
| Jun 11, 2026 | Bollinger Lisa · director | A-Award | 7,657 | $85 |
| Jun 11, 2026 | Fairmount Funds Management LLC · director | A-Award | 7,657 | $85 |
| Jun 11, 2026 | Shah Nimish P · director | A-Award | 7,657 | $85 |
| Jun 11, 2026 | McKenna Mark C. · director | A-Award | 7,657 | $85 |
| Jun 11, 2026 | JONES WILLIAM A JR · director | A-Award | 7,657 | $85 |
| Jun 11, 2026 | Fox Jennifer A. · director | A-Award | 7,657 | $85 |
| Jun 5, 2026 | Dambkowski Carl · officer: Chief Medical Officer | Sale | 5,500 | $79 |
| Jun 5, 2026 | Dambkowski Carl · officer: Chief Medical Officer | M-Exempt | 4,125 | $23 |
| May 15, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 18,659 | $82 |
| May 15, 2026 | HENDERSON MICHAEL THOMAS · director, officer: Chief Executive Officer | Sale | 1,341 | $83 |
| May 8, 2026 | Dambkowski Carl · officer: Chief Medical Officer | Sale | 1,800 | $85 |
| May 8, 2026 | Dambkowski Carl · officer: Chief Medical Officer | M-Exempt | 4,125 | $23 |
| May 8, 2026 | Dambkowski Carl · officer: Chief Medical Officer | Sale | 3,700 | $84 |
| May 4, 2026 | Henderson Jane · officer: Chief Financial Officer | Sale | 289 | $83 |
| May 4, 2026 | Henderson Jane · officer: Chief Financial Officer | Sale | 900 | $83 |
Institutional positioning
13F filings over the trailing two quarters
New 168Increased 191Reduced 126Sold out 49
| Filer | Action | Shares | Filed |
|---|---|---|---|
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Increased | 10,300,984 | May 15, 2026 |
| FMR LLC | Increased | 9,262,291 | May 15, 2026 |
| VR ADVISER, LLC | Unchanged | 8,493,321 | May 15, 2026 |
| VR Adviser, LLC | Unchanged | 8,493,321 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 5,507,032 | Aug 7, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 4,375,703 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 4,085,651 | May 13, 2026 |
| HBK INVESTMENTS L P | New Position | 2,850,000 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Increased | 2,782,097 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,572,119 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,502,095 | May 15, 2026 |
| FMR LLC | Reduced | 2,493,137 | Aug 13, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 2,360,596 | May 18, 2026 |
| STATE STREET CORP | Increased | 2,297,743 | Aug 7, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 2,165,102 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 11, 2026